Sunshine Biopharma regains Nasdaq bid-price compliance; faces 1-year monitoring with strict delisting risk

Sunshine Biopharma Inc.

Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).
Subject to Mandatory Panel Monitor for one year from September 9, 2024.
If non-compliant during monitoring, no cure period allowed; Nasdaq will issue Delist Determination Letter.
Company may request a new hearing if delist determination is issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.